Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8356 to 8370 of 8990 results

  1. Liposomal vincristine for treating Philadelphia chromosome-negative acute lymphoblastic leukaemia after two therapies [ID954]

    Discontinued Reference number: GID-TA11181

    Technology appraisal guidance
    Discontinued

  2. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab for previously treated multiple myeloma (ID1139)

    Discontinued Reference number: GID-TA10193

    Technology appraisal guidance
    Discontinued

  4. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued Reference number: GID-TA10065

    Technology appraisal guidance
    Discontinued

  5. Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

    Discontinued Reference number: GID-TA10179

    Technology appraisal guidance
    Discontinued

  6. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued Reference number: GID-TA10687

    Technology appraisal guidance
    Discontinued

  7. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued Reference number: GID-TA11175

    Technology appraisal guidance
    Discontinued

  8. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued Reference number: GID-TA10264

    Technology appraisal guidance
    Discontinued

  9. Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]

    Discontinued Reference number: GID-TA10213

    Technology appraisal guidance
    Discontinued

  10. Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081]

    Discontinued Reference number: GID-TA10171

    Technology appraisal guidance
    Discontinued

  11. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued Reference number: GID-TA10355

    Technology appraisal guidance
    Discontinued

  12. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued Reference number: GID-TA10365

    Technology appraisal guidance
    Discontinued

  13. Prasterone for the treatment of systemic lupus erythematosus [ID392]

    Discontinued Reference number: GID-TAG373

    Technology appraisal guidance
    Discontinued

  14. Vandetanib for the second line treatment of non-small cell lung cancer [ID46]

    Discontinued Reference number: GID-TAG405

    Technology appraisal guidance
    Discontinued

  15. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued Reference number: GID-TAG330

    Technology appraisal guidance
    Discontinued